Zai Lab (ZLAB) Q4 2025 earnings review
Global R&D Pivot Shadows Missed Commercial Promises
Zai Lab posted 17% YoY revenue growth in 25Q4 to $127.6M, but the results cap a year defined by missed expectations. The company fell $100M+ short of its original 2025 revenue guidance and completely failed to deliver on its highly touted promise of Q4 2025 adjusted profitability (posting a $49.6M adjusted operating loss instead). The former star growth driver, VYVGART, saw sales reverse to $21.9M under the weight of NRDL price rebates and slower adoption. To distract from these commercial missteps in China, management is aggressively pivoting the narrative toward its global oncology pipeline, particularly the 'zoci' DLL3 ADC, which is entering multiple registration-enabling trials.
🐂 Bull Case
Despite intense PARP inhibitor competition, ZEJULA returned to growth (+16% YoY), and newer launches like XACDURO (+225% YoY) and NUZYRA (+45% YoY) are gaining real traction.
The internally developed zocilurtatug pelitecan (zoci) is advancing into three registration-enabling studies by end-of-2026. Early strong clinical data (68-79% ORR in Phase 1) provides a legitimate shot at global market value.
🐻 Bear Case
Management spent H1 2025 promising adjusted operating profitability by Q4. Instead, the Q4 adjusted loss widened to $49.6M, proving their commercial operating leverage model is fundamentally broken.
VYVGART revenue fell YoY to $21.9M. Even adjusting for a $5.6M NRDL rebate, underlying growth has flatlined, contradicting earlier management claims of compounding patient maintenance adoption.
⚖️ Verdict: 🔴
Bearish. The failure to execute on concrete financial promises (both top-line guidance and Q4 profitability) heavily outweighs the early-stage clinical optimism. The aggressive pivot to an R&D narrative appears to be a defensive maneuver to mask China commercial execution issues.
Key Themes
The Profitability Mirage
Reversing. A glaring contradiction to the positive narrative sold earlier in the year emerged in Q4. Management promised adjusted operating profitability by Q4 2025. Instead, Q4 delivered an adjusted operating loss of $49.6M, which actually worsened sequentially from Q3's $28.0M loss and showed no real improvement against 24Q4's $47.6M loss. The promised operating leverage failed to materialize.
VYVGART's Stalled Growth Engine
Decelerating. VYVGART, previously hailed as a >$1B peak sales asset, is struggling. Q4 sales collapsed to $21.9M from $30.0M a year ago. Even adding back the $5.6M NRDL renewal rebate, the $27.5M underlying run-rate is effectively flat sequentially. The slow shift from episodic to maintenance therapy and pricing pressures are choking momentum.
Zoci (ZL-1310) Takes Center Stage
Accelerating. With China commercial struggles apparent, the internally developed zocilurtatug pelitecan (zoci) DLL3 ADC is the new flagship value driver. Zai Lab is advancing three registration-enabling studies across SCLC and NECs by the end of 2026. This represents a massive strategic shift from regional in-licensing to global innovation.
KarXT Commercial Test Imminent
Accelerating. Approved by the NMPA in Dec 2025, KarXT offers the first fundamentally new mechanism of action for schizophrenia in 70 years. The H1 2026 launch will test management's commercial infrastructure. Its early inclusion in China's national treatment guidelines provides a strong macro tailwind for adoption.
Legacy Base Reverses Decline
Accelerating. ZEJULA reversed its earlier struggles against generic PARP competitors, posting an accelerating 16% YoY growth to $56.0M. Similarly, NUZYRA grew 45% YoY to $16.0M, proving that the broader commercial portfolio can still generate vital cash flow.
Macro Reality: NRDL Price Cuts Bite
Stable. The National Reimbursement Drug List (NRDL) renewals remain a double-edged sword in China's healthcare macro environment. While securing access, the mandatory price cuts severely constrain margin expansion. The $5.6M VYVGART rebate in Q4 highlights the punitive nature of these negotiations on top-line growth.
Innovative TCE Expansion
Stable. Zai Lab acquired exclusive worldwide rights to ZL-1311, a T-cell engager (TCE) targeting MUC17 for gastric cancers. This specific technological innovation expands their immuno-oncology portfolio beyond ADCs, highlighting a commitment to owning global rights for novel modalities.
Other KPIs
Accelerating. Reversing the trend of strategic resource optimization seen in Q2 and Q3, R&D spend increased 18% YoY in Q4. This reflects the expensive reality of advancing multiple global trials for zoci and other pipeline assets.
Stable. Total cash declined from $879.7M a year ago. While the balance sheet remains strong, the failure to reach cash flow breakeven means this runway will be tested as expensive late-stage global trials ramp up through 2026.
Guidance
Decelerating. Management completely missed their original full-year revenue guidance of $560-$590M set in Q4 2024 and reaffirmed through H1 2025. While they met the revised floor of 'at least $460M' set in Q3, the massive $100M+ shortfall reflects severe commercial miscalculations.
Reversing. Management promised to achieve adjusted operating profitability by Q4 2025. This target was entirely missed, with the Q4 adjusted operating loss actually widening sequentially.
Key Questions
Profitability Timeline Reality Check
With the Q4 2025 profitability target missed by a wide margin ($49.6M loss), what is the realistic new timeline for breaking even on an adjusted basis, and what structural changes are required to get there?
VYVGART Strategy Post-NRDL
Excluding the $5.6M rebate, VYVGART sales were roughly $27.5M, showing zero sequential growth from Q3. What is the specific strategy to re-accelerate volume enough to offset the new NRDL price cuts?
Funding the Global R&D Ambition
As zoci moves into three registration-enabling trials and ZL-1311 enters the clinic, how much will R&D expenses scale in 2026, and will the current $789M cash balance be sufficient without further dilution?